Kornimate/medical-research-clean huggingface dataset:
relationship between polymorphism of heat shock protein 70 gene and hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: polymorphisms of hsp70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by pcr-rflp or direct sequencing. the clinical relevance of patients will be compared in those with polymorphism and those without.

heat shock protein 70 (hsp 70) may be involved in various aspects of immune system including infection, autoimmunity, and tumor immunity. the relationship between hsp70 expression, disease activity and cancer prognosis varied according to type of cancer. the overexpression of hsp70 by tumor cells contributes to tumor behavior. hsp70 is present in normal and abnormal hepatocytes, and was reported to be over-expressed in both hepatoma cell lines and human hepatocellular carcinoma (hcc) tissue. recent study indicated that hsp70 is a molecular marker during early hepatocarcinogenesis. it is also involved in anti-tumor immunity in hcc.we also investigate the polymorphism of tumor necrosis factor-alpha promoter, and correlated to clinical relevance.

Eligibility criteria:
inclusion criteria: * history proven hcc patients exclusion criteria: * no-definite diagnosed patients

Keywords: heat shock protein70 tumor necrosis factor-alpha promoter polymorphism
vitiligo extent score (ves) score in comparison to vitiligo area and severity index (vasi) score

Conditions: Vitiligo

Summary: all patients with vitiligo attending dermatology outpatient clinic at kasr alainy teaching hospital will be enrolled in this study to compare ves and vasi scores and evaluate them as assessment methods


Eligibility criteria:
inclusion criteria: * age \> 18. * non-segmental vitiligo patients exclusion criteria: * age \< 18 * segmental vitiligo
effectiveness of a multimodal prehabilitation program in patients with bladder cancer undergoing cystectomy

Conditions: Bladder Carcinoma

Summary: currently, the potential value of a multimodal prehabilitation program in bladder cancer has not been extensively studied. the investigators designed the enhance study to assess the effect of a structured multimodal prehabilitation program in 154 patients with bladder cancer on the number (primary endpoint) and severity of complications within 90 days, length of hospital stay, readmissions, physical fitness, muscle strength, physical functioning, nutritional status, smoking behaviour, anxiety and depression, fatigue, quality of life, physical activity, tumor tissue characteristics, and healthcare costs.

the enhance study is a multicenter, randomized controlled trial. the intervention group will participate in a prehabilitation program of 4-6 weeks before surgery, and additionally during neoadjuvant chemotherapy if applicable. the prehabilitation program consist of a tailored exercise program, nutritional support and if relevant smoking cessation and/or psychological counselling. the exercise program is under supervision of an oncology specialized physiotherapist and comprises aerobic-, resistance- and breathing- and relaxation exercises. patients will be asked to be physically active for an additional 2 times a week for at least 30 minutes. a dietician will provide nutritional support and give dietary advice to increase protein intake to enhance the anabolic effect on muscle mass. additionally, patients will receive a supplement containing 30 g of high quality whey-protein daily preferably before sleep and after the supervised training. patients who score high on anxiety and depression will be offered a referral to a psychological support. intensive counselling and nicotine replacement therapy will be offered to all patients who smoke. patients in the intervention group will be asked to keep a diary to track unsupervised activity and to track intake of the protein supplementation. the physical activity level in both groups will be obtained via questionnaire.

Eligibility criteria:
inclusion criteria: * histologically confirmed, primary, bladder cancer (cta-4n0/n+m0), * planned to undergo radical cystectomy, * age ≥ 18 years. exclusion criteria: * subjects with severe cognitive or psychiatric disorders, * subjects who are operated within 3 weeks, * subjects with insufficient command of the dutch language, which precludes them from following study instructions or completing study questionnaires, * subjects who have contraindications to safely perform exercise training or testing (i.e., cpet), * subject who are unable or unwilling to participate in the intervention.

Keywords: prehabilitation bladder cancer exercise smoking cessation nutritional support surgical complications cystectomy
screening of small non-coding rnas as an auxiliary diagnostic biomarker for gastric cancer

Conditions: Stomach Neoplasms

Summary: gastric cancer is one of the most common malignancies of the gastrointestinal system, especially in east asia. a host of patients are diagnosed with gc at the late stage, leading to poor patient prognosis. therefore, there is a strong demand to develop new biomarkers to detect this tumor early. small non-coding rna species include microrna (mirna), piwi-interacting rna (pirna), small interfering rna (sirna), trna-derived small rna (tsrna), etc. it has been demonstrated that small non-coding rnas are involved in gastric cancer cell proliferation, metastasis, progression and survival. hence, it is considered as an auxiliary diagnostic biomarker for gastric cancer.

gastric cancer is one of the most common malignancies of the gastrointestinal system, especially in east asia. a host of patients are diagnosed with gc at the late stage, leading to poor patient prognosis. therefore, there is a strong demand to develop new biomarkers to detect this tumor early. small non-coding rna species include microrna (mirna), piwi-interacting rna (pirna), small interfering rna (sirna), trna-derived small rna (tsrna), etc. it has been demonstrated by previous scientific researches that small non-coding rnas are involved in gastric cancer cell proliferation, metastasis, progression and survival. hence, it is considered as a new biomarker panel for gastric cancer. the purpose of the present clinical trail is to explore the correlation between small non-coding rnas panel and early gastric cancer, and to elucidate the possibility of small non-coding rnas panel as a biomarker for gastric cancer. verify the experimental purpose by monitoring the relative quantification of small non-coding rnas panel through high-throughput sequencing and qrt pcr technology.

Eligibility criteria:
inclusion criteria: * having signed informed consent * age≥ 18 years old and ≤ 85 years old * histologically confirmed gastric cancer exclusion criteria: * other previous malignancy within 5 year * surgery (excluding diagnostic biopsy) within 4 weeks prior to study * pregnancy or lactation period * legal incapacity
intervening on opioid use and loneliness

Conditions: Opioid Use Disorder; Loneliness; Social Isolation

Summary: this study aims to enroll 300 participants who will be assigned to one of three 3 groups. each group will receive an intervention lasting 6, weekly sessions of 40-60 minutes. eligibility include having an opioid use disorder and reporting loneliness or feeling alone or disconnected.

individuals (n = 300) with an opioid use disorder reporting loneliness will be randomized to either (1) therapist-delivered cognitive-behavioral therapy for perceived social isolation, (2) therapist-delivered health education, or (3) self-guided health education. loneliness, opioid and other substance use, the amount of social interactions, social support, and mental and physical health factors prior to starting the treatment, after completing the treatment, and 1, 3, and 6 months following the treatment will be assessed to see how well they work compared to each other.

Eligibility criteria:
inclusion criteria: * must be 18+ * understand english -have internet access- * screen positive for an opioid use disorder * screen positive for elevated loneliness exclusion criteria: * does not understand consent * does not have consistent access to a phone and internet
evaluating the impact of introducing basaglar, a long-acting analog insulin, on clinical and quality of life outcomes in youth with diabetes in bangladesh

Conditions: Type I Diabetes

Summary: this study aimed to determine the effect of introducing basaglar and insulin pen injection devices on clinical and quality of life (qol) parameters in children and young adults with type 1 diabetes in bangladesh

analog insulins are widely used in middle- and high-income countries. however, use of analog insulin remains limited in lower-income countries due to their increased cost and lack of access, and human insulin remains the mainstay of treatment in these settings. long-acting (basal) analog insulin such as glargine have the benefit of a longer duration (up to 24 hours) and a minimal peak action, and generally, only one injection per day is required. although glargine insulin has been shown to reduce the risk of overnight hypoglycemia, consistent improvement in blood glucose control (measured by hba1c) when compared to human insulin has not been shown, and its impact on quality of life is also inconclusive. furthermore, these studies have all been done in highly resourced countries. life for a child (lfac) provides diabetes supplies (insulin, syringes, meters and strips for blood glucose self-monitoring), diabetes-related education, mentoring and technical support to the team managing youth with type 1 diabetes (t1d) managed at the bangladesh institute of research and rehabilitation in diabetes, endocrine and metabolic disorders (birdem) hospital in dhaka, bangladesh. in 2022, lfac commenced supplying basaglar (glargine) insulin with insulin pen devices (humapen ergo ll). this provided a unique opportunity to investigate the effect of introducing glargine (basaglar) insulin in the low-resource setting of bangladesh.

Eligibility criteria:
inclusion criteria: * diagnosed with type 1 diabetes (t1d). diabetes was diagnosed in accordance with world health organization (who) criteria. determination of diabetes type was made by the local investigators according to available clinical features and history: t1d was diagnosed upon abrupt onset of typical symptoms of diabetes with insulin required from diagnosis, and no acanthosis nigricans. they were usually non-obese. * duration of t1d at enrolment \>12 months * aged 10-25 years (inclusive) at time of enrolment * current insulin regimen consisting of humulin nph® and r, or pre-mixed insulin (30/70 r/nph), with no prior use of analogue insulin * attending life for a child, birdem hospital, dhaka for their usual diabetes care exclusion criteria: • previous use of analog insulin

Keywords: analog insulin basaglar bangladesh children and adolescents type 1 diabetes insulin pen-devices
spad in adult patients

Conditions: Specific Antibody Deficiency; Predominantly Antibody Deficiencies

Summary: the detect study aims to demonstrate the importance of detecting spad in adult patients with recurrent benign and/or severe unexplained bacterial upper/lower respiratory tract infections. unlike children in whom the deficit may be transient, long-term strategies are warranted in spad adult patients to prevent severe infections and lung disability. beyond the diagnosis of this still unrecognized pid in adult patients, we want to assess the impact of prophylactic antibiotics or igrt on infections prevention and on quality of life in adult patients with the most severe clinical phenotypes, recurrent infections with high frequency of antibiotics take and/or recurrent infections with complications like bronchiectasis and/or severe infections requiring hospitalizations.


Eligibility criteria:
inclusion criteria: * 18 to 65 year old patients * with a history of recurrent bacterial infections of upper and/or lower respiratory tract for at least 2 years, and fulfilling the specific following criteria: * recurrent benign infections currently requiring 6 courses of antibiotics /year or more, or bilateral bronchiectasis/bronchiolitis (after exclusion of cystic fibrosis and ciliary dyskinesia) and recurrent benign infections currently requiring 3 courses of antibiotics /year or more or a history of severe upper/lower respiratory tract bacterial infection, and/or invasive infection with streptococcus pneumonia, streptococcus pyogenes or haemophilus influenzae, which required hospitalization in the last 2 years, and recurrent benign infections currently requiring 3 courses of antibiotics /year. * normal serum igg, iga, igm and igg subclasses levels, normal ch50 and serum complement c3 and c4 proteins levels, normal t cells count * normal b cell count, normal serum protein electrophoresis and immunofixation. (\* excepted for pseudomonas aeruginosa colonization) exclusion criteria: * any general condition that predisposes to infections: solid or hematological malignancies, diabetes mellitus, severe alcohol or intravenous drug abuse, chronic liver or kidney failure, human immunodeficiency virus infection, anatomic or functional asplenia, drug-induced 1 neutropenia, or solid organ or hematopoietic stem cell transplantation; * any local predisposing factor to infections: cigarette smoking (\> 10 pack-year and/or 5 cigarettes/day), underlying infection (tuberculosis, influenza...), chronic obstructive pulmonary disease, oral, dental or skin conditions favorizing infections, streptococcal skin infections * any other sid or pid diagnosed before inclusion * pregnancy * ppv23 administration in the last 2 years (risk of hyporesponsiveness)

Keywords: specific antibody deficiency predominant antibody deficiencies ig replacement therapy
hypodontia and ovarian cancer

Conditions: Ovarian Cancer; Hypodontia; Breast Cancer; Colon Cancer

Summary: the purpose of this project is to examine whether the risk of developing ovarian cancer is increased in danish women with congenital missing teeth as a result of their failure to develop (hypodontia). should this prove to be the case, these women could be offered regular clinical controls and prophylactic removal of their ovaries when menopause enters and the ovaries are no longer functional (producing hormones). if there is a connection between congenital hypodontia and the development of different types of cancer, the investigators will perform a genetic screening in families with increased risk of cancer and hypodontia for changes in relevant genes, based on the current literature. the investigators hereby search for new genes, which in a changed form leads to an increased risk of cancer and thereby enables us to perform genetic screening in risk families.


Eligibility criteria:
inclusion criteria: * confirmed suspicion of ovarian cancer. exclusion criteria: * suspicion of ovarian cancer disproved.

Keywords: screening genetic cancer
unilateral vs bilateral total hip arthroplasty

Conditions: Osteoarthritis, Hip

Summary: the purpose of the present study was to determine whether unilaterally operated total hip arthroplasty (tha) patients were superior to bilaterally operated tha patients with respect to aerobic endurance capacity, muscle strength and gait patterns 3-5 years after surgery, and to what extent medial femoral head offset (fo) influenced hip abductor strength.


Eligibility criteria:
inclusion criteria: * undergone hip surgery 3-5 years ago * age \< 70 years exclusion criteria: * heart or lung diseases * malign diseases * no muscle/skeletal diseases that compromises testing
safety and efficacy of azelaic acid foam, 15% in papulopustular rosacea

Conditions: Papulopustular Rosacea

Summary: this study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. the study will test the active ingredient plus foam against foam alone.


Eligibility criteria:
inclusion criteria: * signed written informed consent * diagnosis of papulopustular rosacea (iga score of moderate or severe) with a minimum of 12 and maximum of 50 inflammatory lesions (papules and/or pustules) and persistent erythema with or without telangiectasia * free of any clinically significant disease which could interfere with the study * willingness to follow all study procedures * male or female patient at least 18 years of age exclusion criteria: * subjects known to be non-responders to azelaic acid * presence of dermatoses that might interfere with the rosacea diagnosis or the evaluation of treatment results * ocular rosacea, phymatous rosacea * any condition or therapy that in the opinion of the investigator may pose a risk to the patient of interfere with any evaluation in the study * facial laser surgery in the 6 weeks prior to the study * topical or systemic use of prescription or non-prescription medications to treat rosacea * use of any agent other than the investigational drugs to treat rosacea during the study * expected use or change in dose in the 90 days prior to the study of beta-blockers, vasodilators, nsaids, hormonal treatment or drugs causing acneiform eruptions * known hypersensitivity to any ingredients of the investigational product formulation * alcohol or drug abuse * incapability of giving fully informed consent * subject is dependent person, i.e., a relative/family member of the investigator and/or is a member of the investigator's staff * participation in another clinical research study within the last 4 weeks before randomization in this study

Keywords: rosacea papulopustular azelaic acid foam
defining 31phosphorous magnetic resonance spectroscopy characteristics in patients with mitochondrial myopathy

Conditions: Mitochondrial Disease

Summary: this is a developmental protocol to determine the mri based 31p-mrs changes seen in subjects with mitochondrial myopathy using our dynamic exercise protocol and to identify the ideal variable(s) to represent mitochondrial function.


Eligibility criteria:
inclusion criteria: 1. men and women ≥ age 18 years old with primary mitochondrial myopathy 2. known alteration in electron transport chain activity (\<25 % activity of etc) or known mutations in mitochondrial gene. exclusion criteria: failure based on standard clinical mri screening form - the form is intended to establish the safety of subjects participating in the mri scan without divulging any confidentiality information -

Keywords: mitochondria
24-hr iop with travoprost/timolol compared with latanoprost/timolol in xfg

Conditions: Glaucoma

Summary: a crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour iop control and safety of travoprost/timolol fixed combination given once in the evening, versus that of latanoprost/timolol fixed combination given once in the evening in patients with exfoliative glaucoma. the primary objective of this trial is to compare the quality of 24-hour iop control after 3 months of chronic therapy with these two medications.


Eligibility criteria:
inclusion criteria: * patient has xfg and is older than 29 years * the iop without treatment is greater than 25 mm hg and lower than 40 mm hg at baseline (2 readings at 10:00) * patient can be safely washed out without risk for significant deterioration * distance best corrected snelen visual acuity better than 0.1 * no contraindication to prostaglandins or β-blockers * no history of lack of response (\<10% reduction) to any medication * patient can understand the instructions and comply to medications * open normal appearing angles * no sign of ocular infection, except blepharitis, corneal abnormality that may affect iop measurements etc exclusion criteria: * history of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses * patient is a female of childbearing potential or lactating mother

Keywords: 24-hour iop exfoliative glaucoma travoprost/timolol latanoprost/timolol fixed combinations
entecavir prophylaxis for hepatitis b reactivation for cd20 positive b-cell lymphoma patients with resolved hepatitis b (negative hepatitis b surface antigen, positive hepatitis b core antibody)

Conditions: Resolved Hepatitis B; CD20 Positive B-cell Lymphoma

Summary: this phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis b virus (hbv) reactivation that continues until 6 months after completing cd20 monoclonal antibody therapy in patients with cd20-positive b-cell lymphomas and resolved hepatitis b (negative hepatitis b surface antigen, positive hepatitis b core antibody).


Eligibility criteria:
inclusion criteria: * histopathologically confirmed cd20 positive b-cell lymphoma; * plan to receive first-line anti-lymphoma therapy containing cd20 monoclonal antibodies; * negative hbsag, hbv-dna lower than the detection limit and positive anti-hbc at baseline; * total bilirubin less than 1.5x the upper limit of normal (uln), ast and alt less than 2.5x uln; * ecog ps: 0\~2; * estimated survival time \>3 months. exclusion criteria: * positive hbsag or hbv-dna higher than the detection limit at baseline; * previous chemotherapy or radiotherapy for lymphoma; * other primary liver diseases, such as chronic hepatitis c, hepatitis d, autoimmune hepatitis, wilson' s disease or primary biliary cirrhosis; * pregnant or lactating women; * history of immunodeficiency, including positive hiv, or other acquired congenital immunodeficiency disease, or history of organ transplantation.
a study of tnferade™ biologic with concomitant radiotherapy, fluorouracil, and hydroxyurea (tnf-fhx) in patients with head and neck cancer

Conditions: Head and Neck Cancer; Head and Neck Neoplasms

Summary: the primary objective of the first phase is to determine the safety, the maximum tolerated dose (mtd) and dose-limiting toxicity of tnferade in combination with the previously studied combination of fluorouracil (5fu), hydroxyurea (hu) and standard daily radiotherapy in patients with recurrent head and neck cancer (rhnc). all chemoradiotherapy is administered on a "week-on/week-off" schedule. the primary objective of the second phase ii is to determine the locoregional control rate at 24 months.


Eligibility criteria:
inclusion criteria: * head and neck cancer * patients must have a locoregional tumor amenable to reirradiation with curative intent. * disease, or the majority of disease, should be accessible to injection via direct intratumoral injection * life expectancy of greater than 12 weeks * age \> 18 years * ecog performance status 0-1 exclusion criteria: * metastatic disease * history of malignancy (other than head and neck cancer) in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient * patients may not be receiving any other investigational agents currently or within the 4 weeks prior to study day 1 * active infection of any type * chronic treatment for greater than 6 months with steroids * pregnant or lactating women * patients with known history of cerebral vascular disease; stroke or tia within the last 6 months * patients with history of documented thrombosis (pe or dvt), or known coagulopathy or thrombophilia, or evidence of dvt / thromboembolic event upon enrollment * patients receiving hormone replacement therapy or hormonal contraceptives within two weeks of day 1 * patients who have undergone surgery within the last 1 month prior to day 1 * patients with active carotid artery involvement or status post carotid artery graft / stenting

Keywords: head neck cancer neoplasm